Dendreon Corporation

Damir Vidovic

Reiner Laus

Thomas Graddis

Michael Diegel

Itzhak Hakim

Cathy McMahan

Lara Porter Stepan

Provided are alternative reading frame (ARF) polypeptides as well as antigen presenting cell (APC) and dendritic cell (DC) based compositions that comprise ARF polypeptides. ARF polypeptides and ARF polypeptide-based compositions are useful in the treatment of cancer and infectious disease.

Compositions employing alternative reading frame polypeptides for the treatment of cancer and infectious disease

HLA-DR-specific monoclonal antibodies are provided that are capable of inducing apoptosis in HLA-DR-expressing tumor cells. Certain exemplary HLA-DR-specific antibodies exhibit reduced levels of immunosuppressive activity. Antibodies of the present invention will find use in diagnostic methods as well as in compositions and methods for the treatment of cancers associated with HLA-DR expressing tumor cells.

HLA-DR specific antibodies, compositions and methods

Disclosed are immunostimulatory fusion proteins and methods for generating protective DC-induced, T cell-mediated immune responses in vitro and in vivo. The immunostimulatory fusion proteins comprise a polypeptide antigen component and an immunostimulatory component derived from the intracellular domain of the HER-2 protein. Also disclosed are immunostimulatory compositions comprising dendritic cells pulsed with such an immunostimulatory fusion protein and methods for immunotherapy using the compositions.

Compositions and methods for dendritic cell-based immunotherapy

Provided are alternative reading frame (ARF) polypeptides as well as antigen presenting cell (APC) and dendritic cell (DC) based compositions and methods that employ alternative reading frame polypeptides. ARF polypeptides and ARF polypeptide-based compositions and methods are useful in the treatment of cancer and infectious disease.

Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease

Anti-human major histocompatibility complex (MHC) class II, HLA-DR-specific monoclonal antibodies which can induce apoptosis of HLA-DR positive cells are disclosed. The antibodies are used to specifically eliminate HLA-DR antigen positive tumor cells by cross-linking of HLA-DR. Also disclosed are methods for treating cancer using such antibodies, and compositions containing them.

Growing community of inventors

Bellevue, WA, United States of America

Damir Vidovic